Prevail Therapeutics Inc (PRVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | ||
| Net Income | -63,188 | -19,087 |
| Depreciation Amortization | 265 | 526 |
| Accounts payable and accrued liabilities | 3,921 | 976 |
| Other Working Capital | 2,858 | 2,147 |
| Other Operating Activity | 390 | 1,427 |
| Operating Cash Flow | $-55,754 | $-14,011 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -2,136 | -627 |
| Investing Cash Flow | $-2,136 | $-627 |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | 116,303 | N/A |
| Other Financing Activity | 46,624 | 64,907 |
| Financing Cash Flow | $162,927 | $64,907 |
| Beginning Cash Position | 63,105 | 12,836 |
| End Cash Position | 168,142 | 63,105 |
| Net Cash Flow | $105,037 | $50,269 |
| Free Cash Flow | ||
| Operating Cash Flow | -55,754 | -14,011 |
| Capital Expenditure | -2,136 | -627 |
| Free Cash Flow | -57,890 | -14,638 |